

Kidney Fibrosis Therapeutic Pipeline Market Review, H2 2016

*Kidney Fibrosis Treatment Pipeline Review
H2 2016*

PUNE, INDIA, November 9, 2016

/EINPresswire.com/ -- Accumulation of

extracellular matrix in the kidney

causes [kidney fibrosis](#). It is a

progressive disorder characterized by glomerulosclerosis and

tubulointerstitial fibrosis and may lead

to detrimental effects on the kidney

functioning. Predisposing factors are

trauma, injury, infections, surgery,

environmental factors and exposure to

chemicals or radiation. Symptoms include pain, problems related to urination, nausea and

vomiting. The condition may be managed with medication and kidney transplant.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/731522-kidney-fibrosis-pipeline-review-h2-2016>

Report Highlights

Kidney Fibrosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 21 and 7 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Kidney Fibrosis.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Kidney Fibrosis Overview 10

Therapeutics Development 11

Pipeline Products for Kidney Fibrosis - Overview 11

Pipeline Products for Kidney Fibrosis - Comparative Analysis 12

Kidney Fibrosis - Therapeutics under Development by Companies 13

Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15

Kidney Fibrosis - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Kidney Fibrosis - Products under Development by Companies 18

Kidney Fibrosis - Products under Investigation by Universities/Institutes 20

Kidney Fibrosis - Companies Involved in Therapeutics Development 21

AbbVie Inc 21

Angion Biomedica Corp. 22

Bio-inRen 23

BiOrion Technologies B.V. 24

Cellmid Limited 25

Epigen Biosciences, Inc. 26

Evotec AG 27

Galectin Therapeutics, Inc. 28

GenKyoTex S.A. 29

Intercept Pharmaceuticals, Inc. 30

Isarna Therapeutics GmbH 31

Lpath, Inc. 32

MorphoSys AG 33

Pharmaxis Limited 34

ProMetic Life Sciences Inc. 35

Raptor Pharmaceutical Corp. 36

Regulus Therapeutics Inc. 37

Symic Biomedical, Inc. 38

Tobira Therapeutics, Inc. 39

Vascular Biogenics Ltd. 40

Kidney Fibrosis - Therapeutics Assessment 41

Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ANG-3070 - Drug Profile 52
Product Description 52
Mechanism Of Action 52

Access Report @ <https://www.wiseguyreports.com/reports/731522-kidney-fibrosis-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/353154645>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.